|

Are Bundibugyo Ebola Vaccines Available Yet? What the Tumaini Phase 2/3 Trial Means

ByLife Choice Note

Short answer: No licensed Bundibugyo virus disease vaccine has become generally available. On November 4, 2026, a World Health Organization advisory group recommended adding two Bundibugyo-specific vaccine candidates to the ongoing Tumaini Phase 2/3 trial in the Democratic Republic of the Congo. After national authorization, the study will test whether they protect contacts of confirmed cases and continue to assess safety.

Announcement date: November 4, 2026 · Region: outbreak-response research in the Democratic Republic of the Congo · Study population: vaccination rings formed around contacts of confirmed Bundibugyo virus disease cases · Reviewed: November 7, 2026

What changed?

This is an expansion of a clinical trial, not a vaccine approval. WHO’s Technical Advisory Group on Candidate Vaccine Prioritization unanimously recommended that ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469 enter the Tumaini trial. Both candidates were designed specifically for Bundibugyo virus.

The group reviewed preclinical toxicology, challenge studies in ferrets and nonhuman primates, interim Phase 1 safety and immune-response data, manufacturing readiness and dose availability. Those data can justify further study, but they do not yet show that either vaccine prevents infection, severe disease or death in people exposed during an outbreak.

Who is being studied in Tumaini?

Tumaini is an adaptive platform trial that can evaluate several vaccine candidates within one framework. It uses ring vaccination: contacts of a person with confirmed Bundibugyo virus disease are grouped into a vaccination ring. Studying people with a known, recent exposure risk can help researchers estimate protection during an active outbreak.

Ervebo was the first vaccine evaluated in Tumaini. The two Bundibugyo-specific candidates are expected to join after national approvals in the DRC. At the time of WHO’s announcement, four vaccination rings had been established and more were being prepared.

Isn’t Ervebo already an approved Ebola vaccine?

Ervebo is licensed and WHO-prequalified for disease caused by Ebola virus, previously called Zaire ebolavirus. Bundibugyo virus is a different orthoebolavirus species. WHO says there is still insufficient human evidence to determine whether Ervebo protects against Bundibugyo virus disease or how much protection it might provide.

For that reason, WHO recommends that Ervebo use against Bundibugyo virus disease generally take place within a research protocol. An approved Ebola vaccine for one virus species should not be assumed to work against another.

Can travelers or the public receive the new candidates?

  • This is not a vaccination recommendation for the public or for travelers.
  • ChAdOx1 BDBV and mRNA-1469 remain investigational. They are intended for defined trial participants after national review.
  • No human efficacy percentage is available yet. Early evidence focuses on safety, immune responses and animal challenge studies.
  • Initial vaccine-trial results are expected in early 2027. Outbreak dynamics and enrollment can affect timing and statistical certainty.

What are the main limitations?

First, an advisory recommendation is not regulatory approval or a new WHO vaccination policy. Second, an antibody response does not by itself prove protection against infection or death. Third, ring-vaccination trials depend on case detection, contact tracing and the number and timing of new cases. Fourth, uncommon adverse events and the duration of protection require larger numbers and longer follow-up.

WHO also stresses that vaccines alone cannot end an Ebola outbreak. Surveillance, rapid diagnosis, contact tracing, safe care and isolation, infection prevention, safe and dignified burials, and community engagement remain central to control.

What should an individual do with this information?

People considering travel to an affected area should follow current advice from WHO and the relevant national public health authority. Symptoms alone cannot diagnose Ebola, and exposure history matters. Anyone who develops illness after contact with a patient, body fluids or a deceased person in an affected area should call the appropriate health authority or medical service before arriving, so transport and infection-control arrangements can be made safely.

Primary sources

Prepared by: Life Choice Note, an independent personal health-information explainer. This article provides general information and does not diagnose illness, prescribe treatment or replace public health advice.

Related guides